Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 7, 2003. The report is a disclosure of changes in directors' interests in the company's Ordinary Shares, specifically detailing transactions executed by the GlaxoSmithKline Employee Trust ("GSK Trust") on behalf of employee incentive plan participants.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction details rather than financial performance metrics.
Material Changes and Transactions
The following share transactions were reported for October 2003:
- October 1, 2003: The GSK Trust transferred 3,173 Ordinary Shares on behalf of participants in the SmithKline Beecham Mid Term Incentive Plan.
- October 1, 2003: The GSK Trust sold 651 Ordinary Shares on behalf of the same plan at a price of £12.513 per share.
- October 3, 2003: The GSK Trust transferred 13,382 Ordinary Shares on behalf of participants in the SmithKline Beecham Employee Share Option Plan 1991.
The company was advised of these transactions on October 6, 2003.
Management Commentary and Risks
The filing notes that the GSK Trust is a discretionary trust where all current and former employees are potential beneficiaries. Consequently, two directors, Dr. J-P Garnier and Mr. J D Coombe, hold an interest in the shares held by the trust in the same capacity as other employees. No specific risks, contingencies, or unusual items regarding the company's operations were disclosed in this text.
Investor Verification Checklist
- Verify the total number of shares transferred and sold by the GSK Trust during the reporting period.
- Confirm the transaction price of £12.513 per share for the October 1 sale.
- Review the specific incentive plans (Mid Term Incentive Plan and Employee Share Option Plan 1991) associated with the transactions.
- Check for any subsequent filings regarding the directors' interests in the GSK Trust.